Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
VRXA · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Veraxa Biotech Ag - Post De-Spac (VRXA) · oqro.io/stocks/VRXA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.11−0.04 (−3.48%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Veraxa Biotech Ag - Post De-Spac (VRXA) filed 3 open-market purchases in the last 90 days; the latest was filed on Oct 29, 2026.
Since 2026, Veraxa Biotech Ag - Post De-Spac insiders reported 3 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.
No open-market sale by an insider of Veraxa Biotech Ag - Post De-Spac (VRXA) was filed with the SEC in the last 90 days.
No trade in Veraxa Biotech Ag - Post De-Spac (VRXA) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−95.5% (−$23.68) from Jun 11, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $24.79 on Jun 11, 2026 to $1.11 on Nov 13, 2026 (−95.5%). Disclosed in this range: 3 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Zurich. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
Not enough history
Market value
–
Short interest: 91K shares sold short, −15.1% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Traded Oct 27 – Oct 28, 2026 · largest single transaction ~$9.1K
Oct 28, 2026~$9.1K · 9,133 sh @ $1.00
Oct 27, 2026~$850 · 867 sh @ $0.98
DetailsOfficial recordInsider buying
Traded Oct 20 · filed 1 day later
Since the trade +9.9% · S&P 500 −1.9% · to Nov 13
A Veraxa Biotech Ag - Post De-Spac director paid $33K out of pocket for Veraxa Biotech Ag - Post De-Spac shares. 1 other person at Veraxa Biotech Ag - Post De-Spac bought some too, in the same month. Shares held went up 378% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Veraxa Biotech Ag - Post De-Spac reported 3 open-market purchases and 0 sales since 2026; purchases in 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $43K3×3 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Nov 13, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up free